ArticleBMC urology2026
Aquablation for dual burden disease - BPH and chronic prostatitis/chronic pelvic pain syndrome: a single-center prospective pilot study.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) accounts for approximately 90-95% of prostatitis cases and is defined by pelvic pain or discomfort persisting for at least three of the preceding six months in the absence of identifiable infection. Despite its high prevalence, management remains challenging, and no standardized treatment approach has been established. In men with concomitant benign prostatic hyperplasia (BPH), bladder outlet obstruction may contribute to symptom persistence or severity. Aquablation, a robot-assisted, waterjet-based therapy used for the treatment of BPH, enables precise, heat-free prostatic tissue removal and may provide symptomatic benefit in this clinical setting.
methodsWe performed a prospective pilot study including 20 men aged 45 years or older with diagnoses of both BPH and CP/CPPS who reported clinically significant symptoms, defined as an NIH-CPSI score of 8 or greater at screening. All patients underwent Aquablation between July and December 2024 and were evaluated at 1, 3, and 6 months following the procedure. Primary outcome measures included changes in International Prostate Symptom Score (IPSS) and NIH-CPSI, with assessment across pain, urinary, and quality-of-life (QoL) domains.
resultsSignificant improvements in both IPSS and NIH-CPSI scores were observed by 3 months postoperatively (p < .001), with further modest and sustained improvements noted at 6 months. The greatest symptom reductions were seen in pain and quality-of-life domains. No major adverse events occurred during the study period.
conclusionsAquablation was associated with improvement in both lower urinary tract symptoms and CP/CPPS-related symptom measures in men with coexisting BPH and CP/CPPS. These preliminary findings support further investigation of Aquablation as a potential treatment option for selected patients with this challenging clinical overlap.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.